Pharma trial report extraction hits 94% confidence

Overview

An FDA Phase III submission is 200 pages of unstructured text, tables, and chart references, and every field a pharma team extracts from it has to be right.

Building a clinical NLP extraction agent that pulls trial endpoints, adverse events, patient cohorts, and dosages from FDA submission documents requires training data labeled by people who understand the underlying clinical reporting, not generic annotators.

Firstsource enables that training data: certified medical annotation across clinical entities, MedDRA-coded adverse-event tagging, schema validation against source PDFs, and an edge-case corpus covering scanned PDFs, multi-language inserts, and redacted sections.

This was Intelligence that Operates: clinical NLP training data produced under one quality discipline, with regulatory compliance baked into the QA pipeline.

Challenges

• Trial reports aren't documents; they're regulatory submissions. Every extracted field is auditable. A clinical NLP agent trained on generic NER will miss endpoint nuance, drug-dose specifics, and adverse-event coding that regulators expect to be exact.
• Multi-language and adversarial document formats break extraction pipelines. Scanned PDFs, multi-language inserts, and redacted sections show up in real FDA submissions. An agent trained without an adversarial corpus fails on the documents it most needs to handle.
• MedDRA-coded adverse-event annotation requires clinical expertise. Generic annotators can't reliably code Grade 3/4 adverse events or distinguish primary from secondary endpoints. The annotation workforce has to come from clinical research.

How We Made It Happen

We produce the medical annotation, schema validation, and edge-case corpus a clinical trial extraction agent needs to reach FDA-submission accuracy.